Fifteen million people around the world suffer a stroke every year and less that 15% will ever be able to return back to normal life. Our goal is to generate scientific knowledge of the pathophysiology of neurovascular disorders and stroke; cerebral iron dysregulation in the ischemic or hemorrhagic stroke; and multimodal imaging of the pathophysiological hallmarks of the ischemic or haemorrhagic stroke. This knowledge will enable the development of healthcare innovations in the fields of therapy, stratification/classification/predictive biomarkers, and machine/deep learning neurobehavioral assessment. These innovations are tested in proofs of concept in vitro/in silico or in in vivo preclinical models of stroke.

The CMN Research Group promotes an ecosystem of interdisciplinary collaborations to generate new ideas addressed to protecting the brain against stroke. These products of a CMN-developed first-in-class new generation of therapeutic approaches for stroke patients are under development to reduce mortality and provide a better quality of life for survivors.


See the group’s publications here

Members of the Group

Teresa Gasull(ELIMINAR), Group Leader
Octavi Martí-Sistac(ELIMINAR), Co-Leader, Full Senior Lecturer of Physiology (UAB)
Núria deGregorio-Rocasolano(ELIMINAR), Senior Researcher
Marc Melià, PhD Student
Alexia García(ELIMINAR), PhD Student

Jesús Ordoño, Postdoctoral Visiting Scientist (Kintsugi Therapeutics)
Karla Odendaal (Cardiff University), Visiting Erasmus Student
Armand Estévez (UPC), Visiting Student
Núria Mercadé (UPC), Visiting Student

Research lines

1. Novel glutamate-related targets for neuroprotection

The study of the mechanisms driving excitotoxic neuronal death through NMDA-glutamate receptor signalling to find and test targets for neuroprotection.

2. Ferroptosis in neuronal death and antiferroptotic neuroprotective compounds

To understand ferroptosis in neuronal death in stroke and other brain diseases: finding new targets of intervention and new treatments.

3. Experimental modeling of stroke in rodents and swine

Models of ischemic and hemorragic stroke damage in rats, mice and in gyrencephalic, human-like, swine's brain, with a special focus on damage of the white matter and brain areas connectivity.

4. Discovery of new biomarkers to improve stroke treatment

Discovery of new biochemical and bioimaging biomarkers useful to address point of care stroke type identification, stroke patient stratification, patient selection for treatment allocation and/or outcome prediction.

5. Computational biology: machine/deep learning assessment of behaviour in in vivo stroke models

Development of in silico machine/deep learning methods for the neurological analysis of behaviour in stroke models, with predictive value of brain damage and outcome.


Innovative BIomarkers to DIagnose Ischemic stroke: the bet on miRNAs in extracellular vesicles in humanized swine models (IBIDI-Stroke)

PI: Teresa Gasull Dalmau
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI21/0192
Start date: 01/01/2022
End date: 01/01/2025

More information

Apotransferrin to treat acute stroke as a novel neuroprotector strategy /Apotransferrina com a nou tractament per a l'Ictus agut

PI: Teresa Gasull Dalmau
Funding agency: Agencia de Gestio d'ajuts Universitaris i de Recerca AGAUR
Agency code: 2019PROD00120
Start date: 22/07/2020
End date: 22/01/2022

More information

Development of an humanized model of ischemic stroke through endovascular access in the pig for the dynamic study of infarct and cerebral reperfusion

PI: Antoni Dávalos/Teresa Gasull
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI18/01813 
Start date: 01/01/2019
End date: 31/12/2021

Redes de Investigación Cooperativa en Ictus RETICS INVICTUS +

PI: Antoni Dávalos
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: RD16/0019/0020
Start date: 01/01/2017
End date: 31/12/2021

​ ​


Nuevo modelo de ictus reproducible y mínimamente invasivo mediante un abordaje endovascular

Investigadores del Grupo de Investigación en Neurobiología Celular y Molecular (CMN) del IGTP han desarrollado y establecido un modelo de ictus novedoso, reproducible y mínimamente invasivo en el cerdo mediante un abordaje endovascular. El trabajo se ha llevado a cabo en el Centro de Medicina Comparada y Bioimagen (CMCiB), un centro dedicado a la medicina traslacional en el mismo núcleo del Campus Can Ruti de Badalona junto con el IGTP y el Hospital Universitario Germans Trias i Pujol.

- Investigación

Un estudio interactómico identifica una proteína como posible nueva diana terapéutica para prevenir la neurodegeneración post ictus

Un grupo de investigadores liderado desde el Instituto de Investigación Germans Trias i Pujol han llevado a cabo un estudio en profundidad sobre el interactoma DAPK1 en condiciones de ictus. Han identificado las proteínas del interactoma y han destacado una, la LRRFIP1, como una posible diana terapéutica para la neuroprotección después de un ictus. El estudio se ha publicado en la revista Antioixidants.

+ Noticias


Teresa Gasull Dalmau, Group Leader

(+34) 93 033 05 31